Horizon Reports the Completion of Patient Enrollment of Tepezza (teprotumumab-trbw) in P-IV Trial for Thyroid Eye Disease
Shots:
- The company has completed the patient enrollment of the P-IV trial evaluating Tepezza vs PBO in a ratio (2:1) in 57 patients with TED associated with a low CAS. After the treatment is complete, proptosis nonresponders may elect to enter an OLE phase during which they will receive 8 Tepezza infusions
- The primary efficacy of EPs is the change from baseline @24wk. in proptosis & the trial will also evaluate proptosis responder rate, diplopia responder rate, change in orbital pain, change in muscle volume & GO-QoL questionnaire appearance, and visual functioning subscales. The results are expected in Q2’23
- Additionally, the results showed an improvement in debilitating symptoms of TED in patients with inflammatory disease
Ref: Horizon | Image: Horizon
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
